First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI turns negative
Q1 FY2026 Accumulated OCI was -$146K, compared with $391.6M a year earlier.
Context
- Accumulated OCI amounted to 0.1% of total assets at the end of Q1 FY2026.
- Accumulated OCI increased in 1 of the last 2 fiscal years.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- (24K) USD
- Year-over-year change
- -107.9%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (24K) | -107.9% |
| FY2024 | 2024-12-31 | 305K | +138.3% |
| FY2023 | 2023-12-31 | (797K) | — |
Accumulated OCI vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 Accumulated OCI of -$146K is the 8th highest of the 10 companies compared; the peer median is $22K.
- Its year-over-year change of -100.0% is the 6th highest of 9, against a peer median of -90.7%.
- Accumulated OCI amounts to 0.1% of total assets for TRAX, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.06M | -22.1% | -4.4% | 1.6% | |
| Sep 2026 | $519K | -64.2% | -5.0% | 0.1% | |
| Mar 2026 | $322K | -86.5% | +19.8% | 0.1% | |
CLYMClimb Bio, Inc. | Mar 2026 | $157K | -45.1% | — | 0.1% |
| Mar 2026 | $22K | -94.9% | — | 0.0% | |
| Mar 2026 | -$72K | -300.0% | +945333.5% | 0.0% | |
| Jun 2026 | -$79K | — | — | 0.1% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | -$146K | -100.0% | — | 0.1% |
| Mar 2026 | -$146K | -190.7% | — | 0.0% | |
| Jun 2026 | -$930K | -5784.2% | — | 0.4% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $22K | -90.7% | +7.7% | 0.1% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.